---
title: "Xizang Weixinkang Pharmaceutical: Elected Daniel Zhang as Chairman"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238297799.md"
description: "On the evening of April 30th, Xizang Weixinkang Pharmaceutical announced that the board of directors meeting agreed to elect Daniel Zhang as the chairman of the company's fourth board of directors and to elect Liu Feng as the vice chairman of the company's fourth board of directors, with terms consistent with the term of the company's fourth board of directors"
datetime: "2025-04-30T13:04:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238297799.md)
  - [en](https://longbridge.com/en/news/238297799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238297799.md)
generator: "portal-rs"
---

# Xizang Weixinkang Pharmaceutical: Elected Daniel Zhang as Chairman

On the evening of April 30th, Xizang Weixinkang Pharmaceutical announced that the board of directors meeting agreed to elect Daniel Zhang as the chairman of the fourth board of directors of the company and to elect Liu Feng as the vice chairman of the fourth board of directors of the company, with terms consistent with the term of the fourth board of directors of the company

### Related Stocks

- [603676.CN](https://longbridge.com/en/quote/603676.CN.md)

## Related News & Research

- [This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday](https://longbridge.com/en/news/297053341.md)
- [MedicalRite Announces COVID-19 & Flu Combo Test for Better Health](https://longbridge.com/en/news/297204162.md)
- [03:39 ETWalovi Accelerates Global Push with WALOVI Singapore HQ Launch and Trio of Southeast Asia Deals](https://longbridge.com/en/news/297003145.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [OHB-backed Rocket Factory Augsburg signs ESA contract under European Launcher Challenge](https://longbridge.com/en/news/297156222.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**